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Background and aims:There is a clear need for a new approach to the treatment of obe-
sity, which is inexpensive and is effective for establishing lifestyle change. We conducted
a pilot study to evaluate whether dexamphetamine can be used safely, combined with
diet and exercise, for treating obesity. Our ultimate aim is to develop a 6-month treatment
program for establishing the lifestyle changes necessary for weight control, utilizing dex-
amphetamine for its psychotropic effect on motivation. We viewed the anorexigenic effect
as an additional advantage for promoting initial weight loss.
Methods: Obese adults were treated with dexamphetamine for 6 months (maximum of
30 mg twice daily), diet, and exercise. Weight, electrocardiogram, echocardiogram, and
blood pressure were monitored.
Results:Twelve out of 14 completed 6 months treatment. Weight loss by intention to treat
was 10.6 kg (95% CI 5.8–15.5, p<0.001). The mean weight gain in the 6 months after
ceasing dexamphetamine was 4.5 kg (95% CI 1.9–7.2, p=0.003), leaving a mean weight
loss at 12 months from baseline of 7.0 kg (95% CI −13.4 to −0.6, p=0.03). All reported
favorable increases in energy and alertness. Dose-limiting symptoms were mood changes
(2) and insomnia (2). None had drug craving on ceasing dexamphetamine, and there were
no cardiac complications. Among the seven women, there was a significant correlation for
those who lost most weight on treatment to have the least regain in the following 6 months
(r =0.88, p=0.009).
Conclusion: Our treatment with dexamphetamine, diet, and exercise was well tolerated
and effective for initial weight loss. Future research will focus on identifying baseline
predictive variables associated with long-term weight control.
Keywords: obesity, dexamphetamine, weight loss, dose titration, appetite
INTRODUCTION
Obesity is a major risk factor for diabetes, cardiovascular and liver
disease, sleep apnea, some cancers, and osteoarthritis. Despite obe-
sity research being a priority area, current treatment is having little
impact at a population level as weight loss is difficult to achieve
and even harder to sustain (1). Approaches to treatment such as
diet, exercise, pharmacotherapy, and bariatric surgery all have their
drawbacks. Bariatric surgery is becoming accepted as the treatment
of choice for higher levels of obesity,but it is expensive and in some,
weight may subsequently be regained (2). Pharmacotherapy can
assist with weight loss and its efficacy can be enhanced by lifestyle
modification (3). Although there is evidence that exercise assists
with ongoing weight control (4), if medication is ceased weight
is often rapidly regained at a rate proportional to the previous
rate of loss (5). Continuing medication as maintenance treatment
increases expense and risk of side effects. However, a proportion of
individuals are able to achieve and maintain substantial weight loss
(6). The way forward is to find an approach that is able to increase
this proportion. Just as anorexigenic medication assists with ini-
tial weight loss, we suggest that psychotropic medication may assist
with establishing the lifestyle and exercise patterns necessary for
maintaining the weight loss.
Coming from a background of experience in the treatment of
children with attention-deficit hyperactivity disorder (ADHD), we
have observed that dexamphetamine is well tolerated and has few
complications apart from consistently inducing weight loss (7).
ADHD and obesity often coexist, with the characteristic impul-
siveness and poor motivation in ADHD contributing to difficulty
in weight control in some (8). Dexamphetamine has the therapeu-
tic effects of enhancing cognitive control of behavior, improving
motivation, and reducing impulsiveness. It is used in ADHD in
combination with behavioral intervention (multimodal manage-
ment) to promote behavioral change (9–11). By analogy with
ADHD, we postulated that the psychotropic effects of dexam-
phetamine could be utilized in obesity to assist with establishing
new habits to promote long-term weight control. We viewed the
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appetite suppressant effect as an added benefit for assisting with
initial weight loss (12, 13). Dexamphetamine is associated with
more weight loss than methylphenidate (14), perhaps because in
addition to the dopaminergic effects it also inhibits serotonin reup-
take (15). Dexamphetamine is inexpensive. We intended to use it
only for 6 months, which we postulated would be long enough
to establish behavioral change in a proportion of obese individu-
als. Despite its abuse potential, we chose to use dexamphetamine
rather than a selective serotonin reuptake inhibitor (SSRI) because
of its therapeutic effect on behavior, which is intrinsic to the
treatment concept.
The main concerns with dexamphetamine relate to toxicity,
abuse potential, and concern that the small increase in blood
pressure could exacerbate ischemic heart disease (16). However,
amphetamines have been previously studied for the treatment
of obesity (16–19) [including in individuals with cardiovascu-
lar disease (16)] and also for their psychotropic properties (20).
Griffith et al. showed that psychosis can be induced in individ-
uals with no known predisposition within 5 days through dex-
amphetamine doses of 5–15 mg hourly (20). Psychosis is always
preceded by an identifiable pre-psychotic phase associated with
depression, followed by withdrawal and suspicion, and then loss
of insight and extreme paranoia. Psychosis resolves within 1–8 h
after drug withdrawal and is followed by hypersomnolence, irri-
tability, and depression, with complete resolution after 2–3 days
and none of the drug craving characteristic of detoxification from
amphetamine abuse.
In the 1950s in the context of widespread prescription and
misuse of dexamphetamine, there were case reports of amphet-
amine psychosis and malnutrition, together with depression on
drug withdrawal (21). Subsequently, dexamphetamine prescrib-
ing was restricted; its main use over the past 60 years has been
for treating children with ADHD. However, with the rising cost
of obesity (22) and the expense of approved medical and sur-
gical interventions (23), it is timely to question the traditional
teaching that dexamphetamine is too dangerous to use for treating
obesity.
There have been few recent studies that have used ampheta-
mines for treating obesity. In 1947, Ray treated obese patients with
racemic amphetamine and methamphetamine and after 8 months
achieved weight losses of 12.7 kg in men and 11.0 kg in women
(19). More recently, Levy et al. used stimulant medication (mainly
amphetamine) in a predominantly female cohort of obese indi-
viduals, principally to treat newly diagnosed ADHD (12). They
reported weight loss of 15.1± 10.4 kg (12.4± 7.2% of initial body
weight) after an average of 466 days on treatment.
In 2011, Desouza et al. treated veterans with obesity and apathy
with low-dose methylphenidate, to test whether it would improve
motivation and assist with the lifestyle changes required for weight
loss (24). Subjects were randomized to a motivation program with
or without methylphenidate, or to standard nutrition counsel-
ing. Apathy scores improved comparably in all groups, with no
enhancement in those on methylphenidate. However, only those
on methylphenidate achieved statistically significant weight loss
(average 4.6 kg over 6 months). This modest weight loss could
have been due to appetite suppression. This study reported no
psychotropic effects, perhaps because the dose was too low.
In the treatment of ADHD, it is important for the dose of stimu-
lant medication to be individually adjusted to optimize behavioral
functioning. The aims of this pilot study were to investigate the
safety and efficacy of a 6-month period of treatment with dexam-
phetamine for achieving weight loss and to evaluate dose titration
limited by adverse amphetamine symptoms and cardiovascular
effects. The long-term aim of this research is to evaluate whether
behavioral changes can be established safely using dexampheta-
mine and lead to maintenance of weight loss after treatment is
withdrawn.
MATERIALS AND METHODS
This was an open label trial of 6 months of treatment with dex-
amphetamine in adults aged over 18 years with body mass index
(BMI) of more than 30 kg/m2. Exclusion factors included the
following: history of addiction to illicit drugs, uncontrolled hyper-
tension> 140/90, symptomatic ischemic heart disease, significant
kidney or liver disease, uncontrolled epilepsy, history of bariatric
surgery, current treatment with psychotropic medication, systemic
glucocorticoids or medication for weight loss, or family history of
sudden death from cardiac causes.
At baseline, all participants had an echocardiogram and ECG
to screen for cardiomyopathy, valve disease, and arrhythmia. The
ECG was repeated at maintenance dose and the echocardiogram
at the end of the treatment phase. Participants were monitored
weekly during dose titration and monthly while on treatment.
Amphetamine effects were monitored using the Amphetamine
Interview Rating Scale (25).
Our study participants did not come with a diagnosis of ADHD,
so there were no behavioral end points in terms of improvement in
the symptoms of ADHD for guiding dose titration. We, therefore,
progressively increased the dose until either the individual devel-
oped adverse effects necessitating dose reduction or the maximum
formulary dose was reached. The initial dose of dexamphetamine
was 5 mg at breakfast and lunchtime, followed by weekly incre-
mental dose increases of 5 mg twice daily, to a maximum of 30 mg
twice daily. Adverse effects were managed with dose reduction.
At the end of 6 months, the drug was withdrawn and the par-
ticipants were encouraged to maintain the exercise and dietary
changes established on dexamphetamine.
The participants were asked to do 30 min of moderate exercise
for at least 4 days per week and to follow a diet of 7050–7350 kJ
per day, with dietician (Traci L. Cook) assessment at baseline and
review after 2 months on treatment. Behavioral counseling con-
sisted of emphasizing to the participants that the study gave them
a single, unique opportunity to be treated with dexamphetamine
and to use the 6 months of treatment to establish new habits for a
healthy lifestyle. They were given feedback on their progress, with
positive reinforcement for weight loss and reporting a favorable
exercise routine.
Estimated sample size for 90% power to detect a weight
loss of 4% of body weight at two-sided significance of p< 0.05
was 12 based on our data from children (7). The study was
approved by the Nepean and Blue Mountains Local Health Dis-
trict Human Research Ethics Committee, and all participants gave
informed consent. Medication was prospectively approved for
each participant by the NSW Ministry of Health.
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Statistical analysis of the changes in weight, abdominal cir-
cumference, and BMI used paired sample two-tailed Student’s
t -tests.
RESULTS
Between July and November 2012, we recruited 14 participants to
the study, including 2 to cover attrition (Table 1). One discontin-
ued after 4½ months due to side effects but continued to attend
reviews; the other left the study within 2 months for unrelated rea-
sons. Her weight at her final review has been carried forward to
the end of the treatment period for analysis.
The mean weight loss on treatment was 10.6± 8.4 kg,
(p< 0.001), with seven participants (50%) losing more than
10% of their bodyweight. Weight regain in the first 6 months
after stopping treatment reduced the mean weight loss to
7.0± 10.6 kg (p= 0.035), although 3 participants still recorded
a weight reduction of more than 10% and a further 4 of 5–
10%. One woman (who lost 31 kg on treatment) and one man
continued to lose weight after ceasing dexamphetamine (6.3
and 0.4 kg, respectively, in 6 months). Of the 5 who lost more
than 15% of their body weight, 3 recorded no weight regain at
3 months. Among the women, there was a significant correla-
tion between the weight change on treatment and the weight
change in the first 6 months after ceasing treatment (r = 0.88,
p= 0.009), with those who lost most weight showing the least
regain.
Weight loss enabled one participant with obstructive sleep
apnea to cease treatment with continuous positive airways pres-
sure and another with diabetes to have a reduction in insulin. One
participant with borderline hypertension at baseline commenced
antihypertensive treatment, which was continued after completing
the study; another required a reduction in antihypertensives. There
were no cardiac complications.
Nine participants tolerated the full dose of 60 mg/day taken as
two divided doses; 4 remained on lower daily doses of 20 –50 mg.
The participants’ experience of the amphetamine effects is given
in detail in Table 2. This provides data that may be used to evaluate
whether the widespread concern regarding the psychotropic effects
of dexamphetamine justifies the perception that it is too danger-
ous for use in obesity. In two participants, the dose was limited
due to mood changes: one was more aggressive than normal and
the other more emotional and tearful. These improved with dose
reduction in one and the other reduced and then ceased medica-
tion after 4½ months. Two participants took only one dose/day
because of insomnia. Nine experienced a dry mouth, which was
associated with ulcers in three cases. Three reported mild, tran-
sient euphoria, mainly during titration. None reported any drug
withdrawal or problems with ceasing medication at the end of
6 months other than tiredness and hunger. Amphetamine effects
that were perceived as beneficial were increased energy and ability
to concentrate.
DISCUSSION
In our small cohort, we have demonstrated that a relatively short
period of treatment with dexamphetamine and basic behavioral
intervention was effective for weight loss and was not associated
with any significant complications.
The main innovation of this research is the concept of a
relatively short period of treatment with dexamphetamine, uti-
lizing the psychotropic effects on behavior. The strength was
Table 1 | Baseline data and changes in weight, body mass index (BMI), and abdominal circumference after 6 months treatment with
dexamphetamine and changes in the first 6 months after ceasing dexamphetamine (between 6 and 12 months from baseline).
Baseline data Women (n=8) Men (n=6) Total (n=14)
Mean±SD Mean±SD Mean±SD
Age (years) 51.2±27.2 50.2±4.0 50.7±20.1
Height (cm) 161.0±5.0 180.8±2.9 169.5±10.9
Weight (kg) 95.3±15.8 111.8±9.9 102.4±15.6
BMI (kg/m2) 36.7±5.1 34.2±3.4 35.6±4.5
Abdominal circumference (cm) 106.3±8.7 117.0±8.3 110.9±9.9
Changes with treatment Mean (95% CI) Mean (95% CI) Mean (95% CI)
Weight (kg)
Baseline to 6 months −11.9 (−20.1 to −3.7) p=0.01 −9.0 (−15.6 to −2.3) p=0.02 −10.6 (−15.5 to −5.8) p<0.001
6–12 months 5.2 (0.1 to 10.4) p=0.05 3.7 (0.9 to 6.6) p=0.02 4.5 (1.9 to 7.2) p=0.003
BMI (kg/m2)
Baseline to 6 months −4.6 (−7.7 to −1.4) p=0.01 −2.7 (−4.8 to −0.7) p=0.02 −3.8 (−5.6 to −2.0) p=0.001
6–12 months 2.0 (0.1 to 4.0) p=0.05 1.1 (0.3 to 2.0) p=0.02 1.6 (0.6 to 2.6) p=0.004
Abdominal circumference (cm)
Baseline to 6 months −9.8 (−16.5 to −3.2) p=0.01 −8.0 (−15.3 to −0.6) p=0.04 −8.3 (−13.1 to −4.8) p=0.001
6–12 months 4.4 (1.0 to 7.8) p=0.02 4.8 (−0.5 to 10.2) p=0.07 4.6 (2.1 to 7.1) p=0.002
p= significance using two-tailed paired t-tests, statistically significant results in bold.
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Table 2 | Number of participants with any scores (positive or negative) on the Amphetamine Interview Rating Scale at baseline, during titration,
and on maintenance dose of dexamphetamine.
Baseline (n=14) Titration (n=14) Maintenance (n=13) Cessation (n=13)
Activation (includes feeling active, especially alert, excited, talkative, having racing, or sexual thoughts)
Total number experiencing activation 6a 14 9 6a
Depressive affect
Feel depressed 1 (−1) 5 (−0.9) 3 (−0.3) 2 (0)
Have difficulty concentrating 2 (0) 8 (−0.4) 5 (−0.6) 2 (0)
Have difficulty remembering 2 (0) 4 (+0.3) 3 (+0.3) 1 (+1)
Feel guilty 0 4 (−0.6) 2 (−1) 0
Feel sad and pessimistic 3 (−0.3) 5 (−0.5) 4 (−0.5) 1 (+1)
Feel tearful 1 (−1) 6 (+0.1) 4 (−0.5) 1 (+1)
Total number experiencing depressive affect 3 9 6 3
Physical symptoms
Have blurred vision 2 (−1) 1 (+2) 3 (−0.3) 1 (−1)
Feel cold 1 (−1) 4 (+1) 2 (+1) 3 (+1)
Feel dizzy 2 (−2) 3 (+1) 1 (+1) 0
Have dry mouth 3 (−0.7) 9 (+1.4) 8 (+1.2) 1 (−1)
Have a headache 3 (0) 6 (+0.6) 1 (+1) 3 (+1)
Feel hungry 0 11 (−1) 9 (−1) 4 (+0.5)
Feel nauseated 2 (0) 3 (0) 2 (0) 0
Am perspiring 0 3 (+1.3) 4 (+1) 0
Am thirsty 1 (+1) 9 (+1.2) 8 (+1.2) 1 (+1)
Total number experiencing physical symptoms 4 13 11 5
Euphoria (covered by questions of feeling close to people, confident, euphoric, good overall)
Total number experiencing euphoria 3a 9 7 1a
Dysphoria
Feel anxious 2 (−1) 2 (−0.5) 3 (0) 0
Feel angry 1 (−1) 3 (−1) 2 (0) 1 (+1)
Feel irritable 1 (−1) 5 (−0.6) 4 (+0.5) 1 (+1)
Feel less in touch with people 1 (−1) 4 (−0.4) 3 (+0.3) 0
Feel restless 2 (−1) 2 (0) 4 (+1) 1 (+1)
Feel strange 2 (−1) 1 (+1) 0 0
Have unusual thoughts 2 (−1) 2 (−1.5) 0 0
Total number experiencing dysphoria 2 6 8 1
Sleepiness (feeling sleepy or drowsy)
Total number experiencing sleepiness 2 10a 6a 6
aSymptoms experienced as “less than normal.”
They were asked to rate each symptom in relation to “normal” using a five-point scale from −2 to +2 (“much less than normal” to “much more than normal”) with
“normal” as 0. The numbers in brackets give the mean of the symptom score for those who rated the symptom as different from “normal.”
a close monitoring, which found no evidence for any concern
for long-term adverse cardiovascular effects or problems with
abuse or withdrawal from the drug. However, this study was
unable to evaluate the long-term outcomes of multimodal man-
agement combining dexamphetamine with behavioral interven-
tion. This was because participant numbers were restricted to
the minimum required sample size due to practical consider-
ations relating to need to establish the methodology and eth-
ical issues regarding safety. Furthermore, behavioral manage-
ment was limited, and finally, there was no control group for
comparison.
Our results using dexamphetamine compare well with both
previous studies using amphetamines (12, 19) and studies using
other anorexigenic medications. Placebo subtracted weight losses
after 24 or more weeks have been obtained as follows: dexfenflu-
ramine 5.1 kg; phentermine with fenfluramine 9.6 kg; phentamine
with topiramate 8.8 kg; sibutramine 4.2 kg; tesofensine 9.1 kg;
rimonabant 4.7 kg (26). The mean weight loss on placebo in these
studies was 2.4 kg. Extrapolating from this, we might reasonably
anticipate a placebo-subtracted weight loss after 6 months on dex-
amphetamine of around 8.2 kg, which compares well and as a
single drug therapy appears more effective than a SSRI. Although
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a placebo group was not used in this study, the lifestyle advice
regarding diet and exercise in this study was basic and brief, similar
to the studies referenced above, where placebo group weight loss
was small. Greaves et al. conducted a systemic review of reviews
of interventions on the effectiveness of dietary and physical activ-
ity interventions to prevent type 2 diabetes in adults at high risk.
Greaves’ group found that weight loss of 3–5 kg was reported after
lifestyle interventions over 12 months’ duration and 2–3 kg after
36 months’ duration (27).
Combining dexamphetamine with a more structured and
intensive behavioral management program focusing on establish-
ing regular exercise and eating patterns could potentially increase
its efficacy for initial weight loss and for long-term weight control.
We found among the women that there was a significant tendency
for greater weight loss to be associated with less regain. This is
contrary to the expected outcome of a simple, transient period
of amphetamine-induced appetite suppression. It is, therefore,
possible that our rudimentary behavioral intervention worked
synergistically with the dexamphetamine for promoting greater
and more sustained weight loss.
In the search for obesity treatment, the amphetamines have
been largely overlooked. The argument that these are too dan-
gerous is implausible as they have continued to be prescribed for
ADHD. Increasing the therapeutic indications for dexampheta-
mine would certainly lead to more availability and, therefore, more
potential for abuse. However, we believe that there are a large num-
ber of individuals who are struggling to lose weight and would use
dexamphetamine responsibly. Careful participant selection, close
observation, and relatively short treatment period would mini-
mize the opportunity to abuse the drug and would also reduce the
risks of long-term cardiovascular complications.
Our findings need confirmation with a larger, double-blind
placebo-controlled study. Including a more structured behavioral
management program could increase the proportion of individu-
als who achieve sustained weight loss. Testing for cognitive changes
associated with dexamphetamine could provide a useful objective
guide for dose titration. Longer studies are required for correlating
baseline behavioral characteristics with long-term maintenance of
weight loss, in order to be able to predict which individuals are
likely to benefit most. The cost of treatment in terms of the price of
medication is low. We anticipate that a well-monitored 6-month
course of dexamphetamine might become first-line drug treat-
ment for younger people at earlier stages of obesity,where concerns
of cardiovascular side effects are lower due to the lower prevalence
of underlying cardiovascular disease, particularly hypertension. If
the results reported here can be replicated among larger cohorts,
the potential impact of this treatment at a population level is
enormous.
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